Anaphylaxis

Healio has compiled July’s most-read news in asthma and allergy.

The FDA has approved Palforzia for children aged 1 to 3 years who have a peanut allergy that has been diagnosed by a physician, according to a press release from its manufacturer, Stallergenes Greer.

A recent study found that health care professionals were increasingly able to identify infants and young children with anaphylaxis by following modified criteria.

A crossover study revealed that dry powder epinephrine administered via nasal spray yielded drug exposures equal to or higher than those provided by autoinjectors in a canine model.

Modified criteria that incorporated symptoms specific to infants and young children increased identification of anaphylaxis in these age groups, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended marketing authorization of ARS Pharmaceuticals’ EURneffy epinephrine nasal spray in the European Union, according to a press release.

New guidance was established for clinicians in the U.K. in order to implement the use of Palforzia in oral immunotherapy for patients with a peanut allergy, according to a study published in Clinical & Experimental Allergy.

A dry powder epinephrine delivered via a nasal spray yielded drug exposures that were equal to or higher than those achieved through autoinjector in a canine model, according to the results of a study performed by Belhaven Biopharma.

An epinephrine nasal spray is closer to approval in Europe, according to a press release from ARS Pharmaceuticals.

Hypersensitivity to polyethylene glycol may be rare, but when reactions to PEG in drugs do occur, they often are due to molecular weights of 3350 and higher, according to a study published in Annals of Allergy, Asthma & Immunology.